

Electronic Acknowledgement Receipt

EFS ID:	5215316
Application Number:	09589288
International Application Number:	
Confirmation Number:	1519
Title of Invention:	METHODS OF INHIBITING B LYMPHOCYTES USING ANTIBODIES TO NEUTROKINE-ALPHA
First Named Inventor/Applicant Name:	Guo-Liang Yu
Customer Number:	73326
Filer:	John Jr. Kilyk/Himanshu Thakur
Filer Authorized By:	John Jr. Kilyk
Attorney Docket Number:	PF343P3C5
Receipt Date:	24-APR-2009
Filing Date:	08-JUN-2000
Time Stamp:	14:52:26
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	HGSPressRelease-HGSPprogressClinicalTrialsFiveDrugs-2003.pdf	61646 3275a2f8ccf5d814f40690a6ba085838e8634b91	no	6

Warnings:

Information:

2	NPL Documents	HGSPressRelease- HGSReportsFinancialResults4th QY2002-2003.pdf	78930	no	8
			cb051e180d5a263ec9a117019938fd86aa32aa41		
Warnings:					
Information:					
3	NPL Documents	HGSPressRelease- ResultsPhase1ClinicalTrialLymph hostatBinSystemicLupusErythe matosus-2003.pdf	31707	no	4
			0b862f81a56aae46dce99f17bac51543151e3e00		
Warnings:					
Information:					
4	NPL Documents	HGSPressRelease- HGSReportsFinancialResults1st QY2003-2003.pdf	45978	no	4
			e3ee6c25d3e628b06fc2ee14f349fbb7ff34eb81		
Warnings:					
Information:					
5	NPL Documents	HGSPressRelease- HGSUpdateCompanyProgress- 2003.pdf	76135	no	6
			5f6a8a9d0c7e851b0cbefbced6859051e1ffd1b0		
Warnings:					
Information:					
6	NPL Documents	HGSPressRelease- HGSUpdatesProgressClinicalPr ogramsBio2003-2003.pdf	59298	no	5
			2f0b162b11c01883c072270d0b29654f66690c20		
Warnings:					
Information:					
7	NPL Documents	HGSPressRelease- HGSPHase2ClinicalTrialLympho statB-2003.pdf	52786	no	4
			4be79291257bc3111d0334093852515886f5a773		
Warnings:					
Information:					
8	NPL Documents	HGSPressRelease- HGSReportsResultsPhase1Clini calTrialLymphostatB-2003.pdf	59142	no	5
			40ae667e3b418800450719e0ff9ea9d8691613c3		
Warnings:					
Information:					
9	NPL Documents	HGSPressRelease- HGSReports3rdQY2003Financia lResults-2003.pdf	63359	no	7
			6fec424bc3e03f80240378bf640b463d227f4359		
Warnings:					
Information:					
10	NPL Documents	HGSPressRelease- HGSReportsInterimResultsPhas e1Lymphorad131-2003.pdf	56151	no	4
			6edef11cce958f90865688e115c8591b0fcdff662		
Warnings:					
Information:					

11	NPL Documents	HGSPressRelease-HGSInitiatesPhase2ClinicalTrialLymphostatBRheumatoidArthritis-2004.pdf	45370 d62ffdb3187dc6a9c6676cd676476c943c6a093f	no	3
Warnings:					
Information:					
12	NPL Documents	HGSPressRelease-HGSUpdatesProgressSixDrugsClinicalTrials-2004.pdf	48856 34fa6f47d2ae89abbbe9d77733210a0175885a2c	no	4
Warnings:					
Information:					
13	NPL Documents	HGSPressRelease-HGSReportsFinancialResults4thQY-2004.pdf	71490 4676182e4fd1eb7942d1b4b9a75b1812ccc78a3	no	8
Warnings:					
Information:					
14	NPL Documents	HGSPressRelease-HGSAnnoucesSelectionLymphostatBContMarketing-2004.pdf	43836 be3e6b392ee08196c5ab06c3806efc49f6fe29	no	3
Warnings:					
Information:					
15	NPL Documents	HGSPressRelease-HGSPatientEnrollmentPhase2ClinicalTrialLymphostatBRheumatoidArthritis-2004.pdf	45192 f47ca4943d9942c2dc2d97c43bcf11286d1e7be8	no	3
Warnings:					
Information:					
16	NPL Documents	HGSPressRelease-HGSPatientEnrollmentPhase2ClinicalTrialLymphostatBSystLupusErythematosus-2004.pdf	47021 b6237abf7302a83b45440b560ab02223e550f1af	no	4
Warnings:					
Information:					
17	NPL Documents	HGSPressRelease-HGSReportsProgressClinicalTrialsJPMorganConf-2005.pdf	79020 e6acc3bd021d0a7a5d6d80f231e0cfbcf185b04b	no	8
Warnings:					
Information:					
18	NPL Documents	HGSPressRelease-HGSReportsResultsPhase2ClinicalTrialLymphostatBRheumatoidArthritis-2005.pdf	56595 59c92db6efa78043b5dbd4d260d44f60b4d82f69	no	4
Warnings:					
Information:					
19	NPL Documents	HGSPressRelease-GSKOptionLymphostatB-2005.pdf	41958 4dc2880877a6f15b42b49446c16d4ef7e22e6ac3	no	2
Warnings:					
Information:					

20	NPL Documents	HGSPressRelease-HGSConfCallPhase2ClinicalRes ultsLymphostatB-2005.pdf	34613	no	1
			757f131e31e2a4fb9b17f7c29dd1c439d9947e64		
Warnings:					
Information:					
21	NPL Documents	HGSPressRelease-HGSReportsResultsPhase2Clini calTrialLymphostatBSystemicL upusErythematosis-2005.pdf	53848	no	4
			3564456b7c18b4ae3c0669ffa2139e18b9081f5a		
Warnings:					
Information:					
22	NPL Documents	HGSPressRelease-HGSReportsProgress2006Goals JPMorganConf-2006.pdf	99960	no	10
			c11b328b9d0299e6825947f7df903bc5c9d566c5		
Warnings:					
Information:					
23	NPL Documents	HGSPressRelease-HGSPresentationResultsPhase2 ClinicalTrialLymphostatBSLE-2006.pdf	54930	no	3
			c9aff97b341f9bfa783d93952037d22cd6f8274		
Warnings:					
Information:					
24	NPL Documents	PreliminaryNonBindingDecisio nOppositionDivision-EP_1146892-2006.pdf	1071368	no	22
			9f1e5a0f821ab9f1a05dc08ff887ea4cd990a054		
Warnings:					
Information:					
25	NPL Documents	MinutesOralProceedingsOppos itionDivison-EP_1146892-2007. pdf	1613995	no	33
			e799ef5acfd6b344de28a1c13c544dfb3a98838d		
Warnings:					
Information:					
26	NPL Documents	Acosta-Rodriguez-EurJImmunol-2007.pdf	843505	no	11
			f1bd0363752c77c640c6570f89d0e9f1ad679e09		
Warnings:					
Information:					
27	NPL Documents	Badr-Blood-2008.pdf	2007975	no	11
			eabe99ebd0282798469e3deff5b0c77fbb69025c		
Warnings:					
Information:					
28	NPL Documents	Bernstein-CancerRes-1990.pdf	1337899	no	5
			e2e3723336aa0fdfa741c73b692e27d231d86f3f		
Warnings:					
Information:					

29	NPL Documents	Binard- JournalAutoimmunity-2008.pdf	1055701 03b91867598da21418add977fe77fe702c41d442	no	5
Warnings:					
Information:					
30	NPL Documents	Bosello- IntJImmunopatholPharmacol-2007.pdf	962858 9463d83d8bf50b39dc81ae67438f1021fbb e483c	no	8
Warnings:					
Information:					
31	NPL Documents	Buhlmann- JClinicalImmunology-1996.pdf	3130514 dfd7a8c8b3bb8f92df35c6340d4679da41958eb7	no	7
Warnings:					
Information:					
32	NPL Documents	Caliceti-BioconjugChem-1999. pdf	1236691 31465625edbc8c144067e6ec1f3143f95812962e	no	9
Warnings:					
Information:					
33	NPL Documents	Cancro- ImmunologicalReviews-2006. pdf	568463 15aee69157405285f6a5b5fb5c600291febeceec	no	13
Warnings:					
Information:					
34	NPL Documents	Carswell- ProcNatIAcadSci-1975.pdf	1369039 1b97cf7a17ddfd27609b68b850d90188b2899098	no	5
Warnings:					
Information:					
35	NPL Documents	Cerrutti- ImmunologyandCellBiology-2005.pdf	878867 9c718ed190fcded6c981703c9eb1ef90247c966e	no	9
Warnings:					
Information:					
36	NPL Documents	Chang-Blood-2006.pdf	307873 fa23500ec2367bb594b691e2051f6508ab994fa2	no	8
Warnings:					
Information:					
37	NPL Documents	Chatham- ACTACHPAnnualScientificMeeting-2008.pdf	11474361 6732b233068594237b78e9f46fb1ed0ebc760ec9	no	11
Warnings:					
Information:					

38	NPL Documents	Cohen-FundamentalImmunology-1999.pdf	3344678 8e4b2640eefa210cca5a6e8ef097cd1445f036f7	no	24
Warnings:					
Information:					
39	NPL Documents	Couzin-Science-2005.pdf	1161882 a314d9b14a870c645c25f01c456b77392cda983e	no	4
Warnings:					
Information:					
40	NPL Documents	Cragg-BCellTrophicFactors-2005.pdf	2494798 b1c1280b4cdf995fa660b9b875c464c3548158f8	no	35
Warnings:					
Information:					
41	NPL Documents	Cull-ProtocolsinMolecularBiology-1989.pdf	163740 76cf728ead377899079d49617e83962c47ccb53f	no	4
Warnings:					
Information:					
42	NPL Documents	Cull-ProcNatIAcadSciUSA-1992.pdf	1219031 28d6b4d7b04391db875d6edf0bc796e865196c14	no	5
Warnings:					
Information:					
43	NPL Documents	Cwirla-ProcNatIAcadSciUSA-1990.pdf	1119068 6c0056b42cdfc13861e378e8d41b3ba865d389e6	no	5
Warnings:					
Information:					
44	NPL Documents	Czuczman-JClinOncology-1993.pdf	1456345 76e525f689e6b844053089007f96f432ceaa698b	no	9
Warnings:					
Information:					
45	NPL Documents	Davies-NatureGenetics-1993.pdf	163499 6367a8bf934820407685fd21b9ac7155d2c80ed2	no	1
Warnings:					
Information:					
46	NPL Documents	DeNardo-CancerRes-1990.pdf	1081116 dfa932e5a9d4bf212611a5cabd29bbe8ef45b401	no	3
Warnings:					
Information:					

47	NPL Documents	Devlin-Science-1990.pdf	741631	no	4
			562c56a5ba279d9802893b8e57a5bcd13c04f416		
Warnings:					
Information:					
48	NPL Documents	Egner-JClinPathol-2000.pdf	118590	no	9
			55737da002a5f08e75bf38e19c26a39a50c4fea8		
Warnings:					
Information:					
49	NPL Documents	Felici-JMolBiol-1991.pdf	911188	no	10
			51c7ab6ee1a9e436b9d684a764e68b0ef7e70337		
Warnings:					
Information:					
50	NPL Documents	Fell-JImmunol-1991.pdf	1208605	no	7
			660d08f51e5607a083a851be46400446a8dca4d2		
Warnings:					
Information:					
51	NPL Documents	Fishman-Nature-2005.pdf	516583	no	3
			2075d4b191b6af8e8498f386049f9ccb3ab0f2a8		
Warnings:					
Information:					
52	NPL Documents	Fodor-Nature-1993.pdf	212396	no	2
			cdf460834ecd7c6c2eee30b63c103e9a8d4ff2ba9		
Warnings:					
Information:					
53	NPL Documents	Fu-Blood-2006.pdf	1030532	no	9
			5b283051d402e4a4a5c15911d8a6f21fe1edc7f		
Warnings:					
Information:					
54	NPL Documents	Furie-ArthritisResTherapy-2008.pdf	502599	no	15
			f52ae19d42e92e366cac3952d41d6caf2f4604ab		
Warnings:					
Information:					
55	NPL Documents	Gillies-ProcNatIAcadSciUSA-1992.pdf	1013485	no	5
			5b03674717d9d9a2ae6fef92531c7011d3eeb6a0		
Warnings:					
Information:					

56	NPL Documents	Golub- ImmunologyASynthesis-1991. pdf	396664 dbc9bf58f21c1d93e6a2bd58559ffc0f7153 b3bf	no	4
Warnings:					
Information:					
57	NPL Documents	Gruss-Blood-1995.pdf	3150736 bf26056ff65564cdb4c9623f4d0071407890 3808	no	27
Warnings:					
Information:					
58	NPL Documents	Gruss-IntJourClinLabRes-1996. pdf	1766513 b0240b33e19e8e82190e9b331946f83025c cbcd	no	17
Warnings:					
Information:					
59	NPL Documents	Eck-JBiolChem-1989.pdf	1839864 22ddda812dedafb3e449982cfe52ad579db cdd3e	no	11
Warnings:					
Information:					
60	NPL Documents	Falini-Blood-1995.pdf	1885182 e5d5a342d1b32454ec1e94467e6f63404ea 6dd63	no	14
Warnings:					
Information:					
Total Files Size (in bytes):			56665655		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.